Clinical trial Recruiting at 3 sites Interventional Ages 15 to 17

Investigating brain activation in depressed adolescents undergoing Behavioral Activation therapy

Official title: Multi-level Mechanisms of Behavioral Activation Therapy for Adolescent Depression

Run by Emory University · NCT05548244 · Data updated 2026-11-12

This study is testing how Behavioral Activation therapy affects brain activity in depressed teenagers to see if it helps them feel better and be more motivated.

Quick facts

Study typeInterventional
Ages15 Years to 17 Years
SexAll
Enrollment136 (estimated)
SponsorEmory University
Academic / other
Locations3 sites (Atlanta, Georgia and 2 other locations)
StatusRecruiting
StartedJanuary 30, 2023
Main results expectedMay 2027
Study endsMay 2027
Registry record updatedJune 1, 2026
Trial IDNCT05548244 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adolescents aged 15-17 who have a current diagnosis of Major Depressive Disorder.

Probably not a fit

Patients with bipolar disorder, schizophrenia, or other severe mental health conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to compare brain activation patterns in depressed adolescents before, during, and after Behavioral Activation (BA) therapy using functional magnetic resonance imaging (fMRI). The research will focus on understanding how BA influences neural mechanisms related to behavioral avoidance and motivation. A total of approximately 136 participants, including 96 treatment-seeking adolescents and 40 healthy controls, will be recruited to assess both behavioral and neuroimaging measures. The study will involve multiple fMRI sessions to track changes in brain activity associated with symptom improvement.

Why it matters

Potential benefit: If successful, this study could enhance the understanding of how Behavioral Activation therapy works, potentially leading to more effective treatments for adolescent depression.

How similar studies have gone: Other studies have shown promise in using neuroimaging to understand treatment responses in depression, making this approach both relevant and potentially impactful.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Male and female adolescents ages 15-17;
* current MDD diagnosis as determined by K-SADS-PL,
* CDRS-R raw score \> 45 (T-score \> 65) at baseline;
* estimated full scale IQ \> 80 as determined by the WASI-II;
* able to receive outpatient care;
* willing to not partake in other psychosocial treatments;
* not taking psychotropic medications in the two weeks (four weeks for fluoxetine) prior to consent, with the exception of psychostimulant medication prescribed for the treatment of ADHD.
* Additionally, depressed patients must have access to required technology (e.g. smart phone, tablet, or desktop computer) to complete the EMA portion of the study.
* Healthy controls cannot not meet criteria for MDD and their CDRS-R raw score must be below 28; T-score \< 52).

Exclusion Criteria:

* Current or past diagnosis of bipolar, schizophrenia, schizophreniform, schizoaffective disorders, or psychosis NOS;
* current diagnosis of developmental disorder, severe conduct disorder, life-threatening anorexia, OCD, or autism-spectrum disorders;
* taking psychotropic medications prior to entry;
* estimated IQ \< 80; alcohol/drug dependence or abuse within the last 3 months;
* potential/confirmed neurological disorder or epilepsy;
* claustrophobia;
* presence of a medical condition that precludes fMRI;
* endorsement of imminent and serious suicidality;
* medical conditions that take precedence over the presence of MDD;
* pregnancy;
* substance use (excluding nicotine) within two weeks of the fMRI scan;
* left-handedness;
* nicotine use within 3 hours of the fMRI scan;
* history of traumatic brain injury or of being unconscious for more than 30 minutes;
* a stimulant regime for ADHD which has changed within 30 days of the fMRI scan.
* Non-compliance (i.e. \<70% completion) or inability (i.e. lack of smartphone device) to complete the 3 assessment periods of EMA.

Where it's running

  • Emory University
    Atlanta, Georgia, United States
    Recruiting
  • Facility for Education and Research in Neuroscience (FERN)
    Atlanta, Georgia, United States
    Recruiting
  • Child and Adolescent Mood Program (CAMP)
    Atlanta, Georgia, United States
    Recruiting

Study contacts

  • Principal investigator: Michael Treadway, PhD — Emory University
  • Study coordinator: Wade E Craighead, PhD
  • Email: ecraigh@emory.edu
  • Phone: 4047273287

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.